Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma

Stepen Smith, John W. Sweetenham

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Iodine 131 (1131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope 1131.1131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transformed) non-Hodgkin's lymphoma. High response rates in this setting, with some patients achieving a remission of longer duration than that of their prior treatment, provided the basis for approval of the drug. Studies using 1131 tositumomab as initial treatment for low-grade non-Hodgkin's lymphoma (with or without chemotherapy), and in conditioning regimens for autologous transplantation, have yielded promising results. Randomized, comparative trials are needed to define its optimal clinical use.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalFuture Oncology
Volume3
Issue number3
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Therapeutics
Drug Approval
Autologous Transplantation
Radiation Tolerance
Radioisotopes
Anti-Idiotypic Antibodies
Monoclonal Antibodies
iodine-131 anti-B1 antibody
Drug Therapy

Keywords

  • Bexxar®
  • I131
  • Indolent NHL
  • Radioimmunoconjugate
  • Tositumomab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma. / Smith, Stepen; Sweetenham, John W.

In: Future Oncology, Vol. 3, No. 3, 01.06.2007, p. 255-262.

Research output: Contribution to journalArticle

@article{10b187b3dfe448dd844eaa90a143393d,
title = "Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma",
abstract = "Iodine 131 (1131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope 1131.1131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transformed) non-Hodgkin's lymphoma. High response rates in this setting, with some patients achieving a remission of longer duration than that of their prior treatment, provided the basis for approval of the drug. Studies using 1131 tositumomab as initial treatment for low-grade non-Hodgkin's lymphoma (with or without chemotherapy), and in conditioning regimens for autologous transplantation, have yielded promising results. Randomized, comparative trials are needed to define its optimal clinical use.",
keywords = "Bexxar{\circledR}, I131, Indolent NHL, Radioimmunoconjugate, Tositumomab",
author = "Stepen Smith and Sweetenham, {John W.}",
year = "2007",
month = "6",
day = "1",
doi = "10.2217/14796694.3.3.255",
language = "English (US)",
volume = "3",
pages = "255--262",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Iodine 131 tositumomab in the treatment of non-Hodgkins's lymphoma

AU - Smith, Stepen

AU - Sweetenham, John W.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Iodine 131 (1131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope 1131.1131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transformed) non-Hodgkin's lymphoma. High response rates in this setting, with some patients achieving a remission of longer duration than that of their prior treatment, provided the basis for approval of the drug. Studies using 1131 tositumomab as initial treatment for low-grade non-Hodgkin's lymphoma (with or without chemotherapy), and in conditioning regimens for autologous transplantation, have yielded promising results. Randomized, comparative trials are needed to define its optimal clinical use.

AB - Iodine 131 (1131) tositumomab is composed of murine anti-CD20 antibody linked to the radioisotope 1131.1131 tositumomab exploits the specificity of monoclonal antibody therapy and the radiosensitivity of non-Hodgkin's lymphoma to exact a combined antitumor effect. It is currently approved in the USA for treatment of relapsed or refractory low-grade (and transformed) non-Hodgkin's lymphoma. High response rates in this setting, with some patients achieving a remission of longer duration than that of their prior treatment, provided the basis for approval of the drug. Studies using 1131 tositumomab as initial treatment for low-grade non-Hodgkin's lymphoma (with or without chemotherapy), and in conditioning regimens for autologous transplantation, have yielded promising results. Randomized, comparative trials are needed to define its optimal clinical use.

KW - Bexxar®

KW - I131

KW - Indolent NHL

KW - Radioimmunoconjugate

KW - Tositumomab

UR - http://www.scopus.com/inward/record.url?scp=34347371248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347371248&partnerID=8YFLogxK

U2 - 10.2217/14796694.3.3.255

DO - 10.2217/14796694.3.3.255

M3 - Article

C2 - 17547519

AN - SCOPUS:34347371248

VL - 3

SP - 255

EP - 262

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -